Find out why Zacks has assigned United Security Bancshares a "Neutral" rating, being the first on Wall Street to initiate coverage on the stock. Learn how dividends and credit quality are tempered by earnings volatility and rising costs.

COP's strong balance sheet, low debt and resilient cash flow bolster its ability to withstand volatile oil and gas prices.

Hitting record peaks in assets under management (AUM), it may be time to buy the dip in Acadian Asset Management (AAMI) and AllianceBernstein's (AB) stock.

Kevin Simpson, Capital Wealth Planning founder and CIO, joins CNBC's "Halftime Report" to detail his latest Home Depot add.

Stephanie Link, CIO at Hightower, joins CNBC's "Halftime Report" to explain why she's buying more of the software name.

Tesla spent $400,000 advertising on Elon Musk's social media platform X in 2024, according to a new regulatory filing. But the automaker appears to be on track to spend just a fraction of that in 2025 as sales have struggled.

NEW YORK, NY / ACCESS Newswire / September 5, 2025 / For decades, recycling systems have been trapped by the same barrier: national borders. Every country has its own framework, its own set of rules, and its own definition of success.

Universal Health Services, Inc. (NYSE:UHS ) Wells Fargo 20th Annual Healthcare Conference 2025 September 5, 2025 10:15 AM EDT Company Participants Steve Filton - Executive VP, CFO & Secretary Conference Call Participants Stephen Baxter - Wells Fargo Securities, LLC, Research Division Presentation Stephen Baxter Senior Equity Analyst Okay. Good morning, everyone.

It is no secret that Disney's Marvel Studios division doesn't have the same punching power at the box office that it used to.

G-III Apparel Group, Ltd.'s top line is pressured by license losses and tariffs, with owned brands growing but unable to offset the PVH license decline. Gross margins are under significant pressure from tariffs, with further deterioration expected in the coming quarters, impacting earnings outlook. Despite strong brands, no debt, and insider ownership, the company faces its toughest period ahead due to macro and industry headwinds.

Braze, Inc. (NASDAQ:BRZE ) Citi's 2025 Global Technology, Media and Telecommunications Conference September 5, 2025 8:50 AM EDT Company Participants William Magnuson - Co-Founder, Chairman & CEO Isabelle Winkles - Chief Financial Officer Conference Call Participants Tyler Radke - Citigroup Inc., Research Division Presentation Tyler Radke VP & Senior Analyst Happy Friday, and welcome to day 3 of Citi Tech Conference. I'm Tyler Radke, Citi's Co-Head of U.S. Software.

Candel Therapeutics' CAN-2409 shows robust, multi-cancer efficacy with significant survival gains in prostate, pancreatic, and lung cancers, plus promising early glioblastoma data. The company is financially solid after a $92 million capital raise, ensuring a cash runway through 2027 and supporting late-stage clinical and regulatory milestones. Candel's differentiated oncolytic viral platform and FDA Fast Track designations position it as a leader in a rapidly maturing immuno-oncology niche.

Unfortunately, you won't earn high yields with today's savings accounts. So, if it's dependability you're after, with yield to boot, you can't go wrong with a safe ETF.

Transaction in Own Shares 5 September, 2025 • • • • • • • • • • • • • • • • Shell plc (the ‘Company') announces that on 5 September, 2025 it purchased the following number of Shares for cancellation. Aggregated information on Shares purchased according to trading venue: Date of purchase Number of Shares purchased Highest price paid Lowest price paid Volume weighted average price paid per share Venue Currency 05/09/2025 677,502 £26.9200 £26.2600 £26.5329 LSE GBP 05/09/2025 172,529 £26.9200 £26.4100 £26.7040 Chi-X (CXE) GBP 05/09/2025 398,676 £26.9200 £26.2650 £26.5063 BATS (BXE) GBP 05/09/2025 801,058 €31.2050 €30.4050 …

GE Aerospace teams up with BETA to develop hybrid electric turbogenerators, aiming to boost range, payload and performance in next-gen aircraft.

Aquestive Therapeutics's Anaphylm could be the first FDA-approved, non-invasive, orally delivered epinephrine for anaphylaxis, with a PDUFA date set for January 2026. FDA's decision not to convene an advisory committee is a positive signal, and clinical data seems to strongly support Anaphylm's safety and efficacy. If approved, Anaphylm could capture significant market share, potentially driving Aquestive's valuation above $1bn and offering >50% upside for investors.

Tesla is asking investors to approve yet another outsized pay plan for CEO Elon Musk, according to a financial filing out Friday. The total package is worth about $975 billion based on the maximum payout.

U.S. stocks were struggling in early-afternoon trading Friday, as the latest jobs data for August helped revive investors' worries about a slowing labor market.

KO posts 5% organic revenue growth in Q2, extends its value share streak and leans on local execution to fuel resilience.

Ulta Beauty debuts in Mexico with new stores, exclusive brands and immersive experiences, marking its international expansion.